BackBone Biologics Overview

Bone Biologics Long Term Debt

Bone Biologics's long-term debt is $0.

Get informed when a big investor buys or sells

+ Follow
Long Term Debt
$0.00

Peer trimmed avg / median

Loading

Bone Biologics Long Term Debt History

Loading

Bone Biologics vs. peers: Long Term Debt Comparison

Loading

Bone Biologics Long Term Debt Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Bone Biologics (BBLG) FAQ

Bone Biologics posts a long-term debt of $0 as of June 2026. In the prior-year period, the figure was $0. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Bone Biologics's long-term debt was $0. The latest reading is $0 (period ending June 2026). Use the history and growth charts on this page for a longer lookback.

Long-Term Debt is one piece of Bone Biologics's financial statement story. At $0, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for BBLG's long-term debt usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Bone Biologics's other metric pages and overview cover the third.